Abstract
In recent years, immunotherapy has emerged as a novel antitumor strategy in addition to traditional surgery, radiotherapy and chemotherapy. It uniquely focuses on immune cells and immunomodulators in the tumor microenvironment and helps eliminate tumors at the root by rebuilding the immune system. Despite remarkable breakthroughs, cancer immunotherapy still faces many challenges: lack of predictable and prognostic biomarkers, adverse side effects, acquired treatment resistance, high costs, etc. Therefore, more efficacious and efficient, safer and cheaper antitumor immunomodulatory drugs have become an urgent requirement. For decades, plant-derived natural products obtained from land and sea have provided the most important source for the development of antitumor drugs. Currently, more attention is being paid to the discovery of potential cancer immunotherapy modulators from plant-derived natural products, such as polysaccharides, phenols, terpenoids, quinones and alkaloids. Some of these agents have outstanding advantages of multitargeting and low side effects and low cost compared to conventional immunotherapeutic agents. We intend to summarize the progress of comprehensive research on these plant-derived natural products and their derivatives and discuss their possible mechanisms in regulating the immune system and their efficacy as monotherapies or in combination with regular chemotherapeutic agents.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abbott M, Ustoyev Y (2019) Cancer and the immune system: the history and background of immunotherapy. Semin Oncol Nurs 35:150923. https://doi.org/10.1016/j.soncn.2019.08.002
Abudabbus A, Badmus JA, Shalaweh S, Bauer R, Hiss D (2017) Effects of fucoidan and chemotherapeutic agent combinations on malignant and non-malignant breast cell lines. Curr Pharm Biotechnol 18:748–757. https://doi.org/10.2174/1389201018666171115115112
Armengol M, Santos JC, Fernandez-Serrano M, Profitos-Peleja N, Ribeiro ML, Roue G (2021) Immune-checkpoint inhibitors in B-cell lymphoma. Cancers (basel) 13:214. https://doi.org/10.3390/cancers13020214
Arneth B (2019) Tumor microenvironment. Medicina (kaunas) 56:15. https://doi.org/10.3390/medicina56010015
Azimi Mohamadabadi M, Hassan ZM, Zavaran Hosseini A, Gholamzad M, Noori S, Mahdavi M, Maroof H (2013) Arteether exerts antitumor activity and reduces CD4+CD25+FOXP3+ T-reg cells in vivo. Iran J Immunol 10:139–149
Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 16:223–249. https://doi.org/10.1146/annurev-pathol-042020-042741
Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, Malachowski WP, Prendergast GC, Muller AJ (2008) A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 27:2851–2857. https://doi.org/10.1038/sj.onc.1210939
Belcaro G, Hosoi M, Pellegrini L, Appendino G, Ippolito E, Ricci A, Ledda A, Dugall M, Cesarone MR, Maione C, Ciammaichella G, Genovesi D, Togni S (2014) A controlled study of a lecithinized delivery system of curcumin (Meriva(R)) to alleviate the adverse effects of cancer treatment. Phytother Res 28:444–450. https://doi.org/10.1002/ptr.5014
Bhaw-Luximon A, Jhurry D (2017) Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives. Cancer Chemother Pharmacol 79:451–466. https://doi.org/10.1007/s00280-017-3251-7
Boland P, Heath J, Sandigursky S (2020) Immune checkpoint inhibitors and vasculitis. Curr Opin Rheumatol 32:53–56. https://doi.org/10.1097/BOR.0000000000000672
Borregaard N (2010) Neutrophils, from marrow to microbes. Immunity 33:657–670. https://doi.org/10.1016/j.immuni.2010.11.011
Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70:9003–9011. https://doi.org/10.1158/0008-5472.CAN-10-2364
Cao Y, Feng YH, Gao LW, Li XY, Jin QX, Wang YY, Xu YY, Jin F, Lu SL, Wei MJ (2019) Artemisinin enhances the anti-tumor immune response in 4T1 breast cancer cells in vitro and in vivo. Int Immunopharmacol 70:110–116. https://doi.org/10.1016/j.intimp.2019.01.041
Chen D, Xie J, Fiskesund R, Dong W, Liang X, Lv J, Jin X, Liu J, Mo S, Zhang T, Cheng F, Zhou Y, Zhang H, Tang K, Ma J, Liu Y, Huang B (2018) Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Nat Commun 9:873. https://doi.org/10.1038/s41467-018-03225-9
Chin EN, Yu C, Vartabedian VF, Jia Y, Kumar M, Gamo AM, Vernier W, Ali SH, Kissai M, Lazar DC, Nguyen N, Pereira LE, Benish B, Woods AK, Joseph SB, Chu A, Johnson KA, Sander PN, Martinez-Pena F, Hampton EN, Young TS, Wolan DW, Chatterjee AK, Schultz PG, Petrassi HM, Teijaro JR, Lairson LL (2020) Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science 369:993–999. https://doi.org/10.1126/science.abb4255
Choi JG, Kim YS, Kim JH, Kim TI, Li W, Oh TW, Jeon CH, Kim SJ, Chung HS (2020) Anticancer effect of salvia plebeia and its active compound by improving T-cell activity via blockade of PD-1/PD-L1 interaction in humanized PD-1 mouse model. Front Immunol 11:598556. https://doi.org/10.3389/fimmu.2020.598556
Chowdhury PS, Chamoto K, Honjo T (2018) Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. J Intern Med 283:110–120. https://doi.org/10.1111/joim.12708
Coffelt SB, Wellenstein MD, De Visser KE (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16:431–446. https://doi.org/10.1038/nrc.2016.52
Corrales L, Glickman LH, Mcwhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW Jr, Gajewski TF (2015) Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 11:1018–1030. https://doi.org/10.1016/j.celrep.2015.04.031
Couillard-Montminy V, Gagnon PY, Fortin S, Cote J (2019) Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer. J Oncol Pharm Pract 25:44–51. https://doi.org/10.1177/1078155217724595
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867. https://doi.org/10.1038/nature01322
Crusz SM, Miller RE (2020) Targeted therapies in gynaecological cancers. Histopathology 76:157–170. https://doi.org/10.1111/his.14009
De Miguel M, Calvo E (2020) Clinical challenges of immune checkpoint inhibitors. Cancer Cell 38:326–333. https://doi.org/10.1016/j.ccell.2020.07.004
Deberardinis RJ (2020) Tumor microenvironment, metabolism, and immunotherapy. N Engl J Med 382:869–871. https://doi.org/10.1056/NEJMcibr1914890
Deng Y, Chu J, Ren Y, Fan Z, Ji X, Mundy-Bosse B, Yuan S, Hughes T, Zhang J, Cheema B, Camardo AT, Xia Y, Wu LC, Wang LS, He X, Kinghorn AD, Li X, Caligiuri MA, Yu J (2014) The natural product phyllanthusmin C enhances IFN-gamma production by human NK cells through upregulation of TLR-mediated NF-kappaB signaling. J Immunol 193:2994–3002. https://doi.org/10.4049/jimmunol.1302600
Deng LJ, Qi M, Li N, Lei YH, Zhang DM, Chen JX (2020) Natural products and their derivatives: promising modulators of tumor immunotherapy. J Leukoc Biol 108:493–508. https://doi.org/10.1002/JLB.3MR0320-444R
Dill EA, Dillon PM, Bullock TN, Mills AM (2018) IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1. Mod Pathol 31:1513–1522. https://doi.org/10.1038/s41379-018-0061-3
Ding C, Li J, Jiao M, Zhang A (2016) Catalyst-free sp(3) C-H acyloxylation: regioselective synthesis of 1-acyloxy derivatives of the natural product tanshinone IIA. J Nat Prod 79:2514–2520. https://doi.org/10.1021/acs.jnatprod.6b00370
Du H, Xu T, Cui M (2021) cGAS-STING signaling in cancer immunity and immunotherapy. Biomed Pharmacother 133:110972. https://doi.org/10.1016/j.biopha.2020.110972
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998. https://doi.org/10.1038/ni1102-991
Egen JG, Ouyang W, Wu LC (2020) Human anti-tumor immunity: insights from immunotherapy clinical trials. Immunity 52:36–54. https://doi.org/10.1016/j.immuni.2019.12.010
Etzerodt A, Tsalkitzi K, Maniecki M, Damsky W, Delfini M, Baudoin E, Moulin M, Bosenberg M, Graversen JH, Auphan-Anezin N, Moestrup SK, Lawrence T (2019) Specific targeting of CD163(+) TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression. J Exp Med 216:2394–2411. https://doi.org/10.1084/jem.20182124
Flood BA, Higgs EF, Li S, Luke JJ, Gajewski TF (2019) STING pathway agonism as a cancer therapeutic. Immunol Rev 290:24–38. https://doi.org/10.1111/imr.12765
Franzoi MA, Romano E, Piccart M (2021) Immunotherapy for early breast cancer: too soon, too superficial, or just right? Ann Oncol 32:323–336. https://doi.org/10.1016/j.annonc.2020.11.022
Gajewski TF, Higgs EF (2020) Immunotherapy with a sting. Science 369:921–922. https://doi.org/10.1126/science.abc6622
Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S (2013) Tumor associated macrophages and neutrophils in cancer. Immunobiology 218:1402–1410. https://doi.org/10.1016/j.imbio.2013.06.003
Galon J, Bruni D (2020) Tumor immunology and tumor evolution: intertwined histories. Immunity 52:55–81. https://doi.org/10.1016/j.immuni.2019.12.018
Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC, Investigators K (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092. https://doi.org/10.1056/NEJMoa1801005
Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14:120–125
Gong C, Yao C, Xu Z, Ni Z, Zhu X, Wang L, Yan X, Zhou W, Zhu S (2017) Enhancement of NK cell-mediated lysis of non-small lung cancer cells by nPKC activator, ingenol 3,20 dibenzoate. Mol Immunol 83:23–32. https://doi.org/10.1016/j.molimm.2017.01.012
Gu YZ, Zhao X, Song XR (2020) Ex vivo pulsed dendritic cell vaccination against cancer. Acta Pharmacol Sin 41:959–969. https://doi.org/10.1038/s41401-020-0415-5
Hacking S, Chavarria H, Jin C, Perry A, Nasim M (2020) Landscape of immune checkpoint inhibition in carcinosarcoma (MMMT): analysis of IDO-1, PD-L1 and PD-1. Pathol Res Pract 216:152847. https://doi.org/10.1016/j.prp.2020.152847
He ZY, Shi CB, Wen H, Li FL, Wang BL, Wang J (2011) Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest 29:208–213. https://doi.org/10.3109/07357907.2010.550592
He G, Zhang H, Zhou J, Wang B, Chen Y, Kong Y, Xie X, Wang X, Fei R, Wei L, Chen H, Zeng H (2015) Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 34:141. https://doi.org/10.1186/s13046-015-0256-0
He Q, Liu Z, Liu Z, Lai Y, Zhou X, Weng J (2019) TCR-like antibodies in cancer immunotherapy. J Hematol Oncol 12:99. https://doi.org/10.1186/s13045-019-0788-4
Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, Lebleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, Mcbride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautes-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA (2020) B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577:549–555. https://doi.org/10.1038/s41586-019-1922-8
Ho DH, Wong RH (2018) TNP-470 skews DC differentiation to Th1-stimulatory phenotypes and can serve as a novel adjuvant in a cancer vaccine. Blood Adv 2:1664–1679. https://doi.org/10.1182/bloodadvances.2017013433
Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, Brown K, Steward WP, Gescher AJ (2011) Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases–safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (phila) 4:1419–1425. https://doi.org/10.1158/1940-6207.CAPR-11-0148
Hsu HY, Lin TY, Hu CH, Shu DTF, Lu MK (2018) Fucoidan upregulates TLR4/CHOP-mediated caspase-3 and PARP activation to enhance cisplatin-induced cytotoxicity in human lung cancer cells. Cancer Lett 432:112–120. https://doi.org/10.1016/j.canlet.2018.05.006
Hu M, Yang J, Qu L, Deng X, Duan Z, Fu R, Liang L, Fan D (2020) Ginsenoside Rk1 induces apoptosis and downregulates the expression of PD-L1 by targeting the NF-kappaB pathway in lung adenocarcinoma. Food Funct 11:456–471. https://doi.org/10.1039/c9fo02166c
Huang MY, Jiang XM, Xu YL, Yuan LW, Chen YC, Cui G, Huang RY, Liu B, Wang Y, Chen X, Lu JJ (2019) Platycodin D triggers the extracellular release of programed death Ligand-1 in lung cancer cells. Food Chem Toxicol 131:110537. https://doi.org/10.1016/j.fct.2019.05.045
Hunt S, Yoshida M, Davis CE, Greenhill NS, Davis PF (2015) An extract of the medicinal plant Artemisia annua modulates production of inflammatory markers in activated neutrophils. J Inflamm Res 8:9–14. https://doi.org/10.2147/JIR.S75484
Ikeguchi M, Yamamoto M, Arai Y, Maeta Y, Ashida K, Katano K, Miki Y, Kimura T (2011) Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer. Oncol Lett 2:319–322. https://doi.org/10.3892/ol.2011.254
Ishihara S, Yamada Y, Iwasaki T, Yoshimoto M, Toda Y, Kohashi K, Yamamoto H, Matsumoto Y, Nakashima Y, Oda Y (2021) PDL1 and IDO1 expression in undifferentiated pleomorphic sarcoma: the associations with tumor infiltrating lymphocytes, dMMR and HLA class I. Oncol Rep 45:379–389. https://doi.org/10.3892/or.2020.7837
Jaillon S, Galdiero MR, Del Prete D, Cassatella MA, Garlanda C, Mantovani A (2013) Neutrophils in innate and adaptive immunity. Semin Immunopathol 35:377–394. https://doi.org/10.1007/s00281-013-0374-8
Jiang Z, Okimura T, Yamaguchi K, Oda T (2011) The potent activity of sulfated polysaccharide, ascophyllan, isolated from Ascophyllum nodosum to induce nitric oxide and cytokine production from mouse macrophage RAW264.7 cells: comparison between ascophyllan and fucoidan. Nitric Oxide 25:407–415. https://doi.org/10.1016/j.niox.2011.10.001
Jiang M, Li W, Zhu C, Li X, Zhang J, Luo Z, Qin B, Du Y, Luo L, You J (2021) Perdurable PD-1 blockage awakes anti-tumor immunity suppressed by precise chemotherapy. J Control Release 329:1023–1036. https://doi.org/10.1016/j.jconrel.2020.10.031
Jo SK, Hong JY, Park HJ, Lee SK (2012) Anticancer activity of novel daphnane diterpenoids from daphne genkwa through cell-cycle arrest and suppression of akt/stat/src signalings in human lung cancer cells. Biomol Ther (seoul) 20:513–519. https://doi.org/10.4062/biomolther.2012.20.6.513
Joseph MM, Aravind SR, Varghese S, Mini S, Sreelekha TT (2012) Evaluation of antioxidant, antitumor and immunomodulatory properties of polysaccharide isolated from fruit rind of Punica granatum. Mol Med Rep 5:489–496. https://doi.org/10.3892/mmr.2011.638
Joseph MM, Aravind SR, George SK, Varghese S, Sreelekha TT (2013) A galactomannan polysaccharide from Punica granatum imparts in vitro and in vivo anticancer activity. Carbohydr Polym 98:1466–1475. https://doi.org/10.1016/j.carbpol.2013.07.023
Kang HB, Ahn KS, Oh SR, Kim JW (2014) Genkwadaphnin induces IFN-gamma via PKD1/NF-kappaB/STAT1 dependent pathway in NK-92 cells. PLoS ONE 9:e115146. https://doi.org/10.1371/journal.pone.0115146
Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14:642–662. https://doi.org/10.1038/nrd4663
Ke M, Zhang Z, Xu B, Zhao S, Ding Y, Wu X, Wu R, Lv Y, Dong J (2019) Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells. Int Immunopharmacol 75:105824. https://doi.org/10.1016/j.intimp.2019.105824
Kiani BH, Kayani WK, Khayam AU, Dilshad E, Ismail H, Mirza B (2020) Artemisinin and its derivatives: a promising cancer therapy. Mol Biol Rep 47:6321–6336. https://doi.org/10.1007/s11033-020-05669-z
Kim HJ, Yoon YM, Lee JH, Lee SH (2019) Protective role of fucoidan on cisplatin-mediated ER stress in renal proximal tubule epithelial cells. Anticancer Res 39:5515–5524. https://doi.org/10.21873/anticanres.13744
Kim JH, Kim YS, Choi JG, Li W, Lee EJ, Park JW, Song J, Chung HS (2020) Kaempferol and its glycoside, kaempferol 7-O-rhamnoside, inhibit PD-1/PD-L1 interaction in vitro. Int J Mol Sci 21:3239. https://doi.org/10.3390/ijms21093239
Kinghorn AD, Ej DEB, Lucas DM, Rakotondraibe HL, Orjala J, Soejarto DD, Oberlies NH, Pearce CJ, Wani MC, Stockwell BR, Burdette JE, Swanson SM, Fuchs JR, Phelps MA, Xu L, Zhang X, Shen YY (2016) Discovery of anticancer agents of diverse natural origin. Anticancer Res 36:5623–5637. https://doi.org/10.21873/anticanres.11146
Kupchan SM, Uchida I, Branfman AR, Dailey RG Jr, Fei BY (1976) Antileukemic principles isolated from euphorbiaceae plants. Science 191:571–572. https://doi.org/10.1126/science.1251193
Langroudi L, Hassan ZM, Ebtekar M, Mahdavi M, Pakravan N, Noori S (2010) A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model. Int Immunopharmacol 10:1055–1061. https://doi.org/10.1016/j.intimp.2010.06.005
Lee S, Margolin K (2011) Cytokines in cancer immunotherapy. Cancers (basel) 3:3856–3893. https://doi.org/10.3390/cancers3043856
Lee HT, Lee SH, Heo YS (2019) Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology. Molecules 24:1190. https://doi.org/10.3390/molecules24061190
Li S, Chou G, Hseu Y, Yang H, Kwan H, Yu Z (2013) Isolation of anticancer constituents from flos genkwa (Daphne genkwa Sieb.et Zucc.) through bioassay-guided procedures. Chem Cent J 7: 159. https://doi.org/10.1186/1752-153X-7-159.
Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X, Wang H (2017) Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut 66:157–167. https://doi.org/10.1136/gutjnl-2015-310514
Li B, Chan HL, Chen P (2019) Immune checkpoint inhibitors: basics and challenges. Curr Med Chem 26:3009–3025. https://doi.org/10.2174/0929867324666170804143706
Li-Weber M (2015) Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines). Int J Cancer 137:1791–1799. https://doi.org/10.1002/ijc.29013
Liang M, Fu J (2008) Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells. Cancer Lett 270:337–341. https://doi.org/10.1016/j.canlet.2008.05.025
Liao F, Liu L, Luo E, Hu J (2018) Curcumin enhances anti-tumor immune response in tongue squamous cell carcinoma. Arch Oral Biol 92:32–37. https://doi.org/10.1016/j.archoralbio.2018.04.015
Lin X, Lu X, Luo G, Xiang H (2020) Progress in PD-1/PD-L1 pathway inhibitors: from biomacromolecules to small molecules. Eur J Med Chem 186:111876. https://doi.org/10.1016/j.ejmech.2019.111876
Liu J, Chen X, Ward T, Pegram M, Shen K (2016) Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. Tumour Biol 37:9825–9835. https://doi.org/10.1007/s13277-015-4650-1
Liu HQ, Zou BQ, Wang SY (2017) Expression and prognostic values of PD-1, PD-L1 and IDO-1 in sinonasal malignant mucosal melanoma. Zhonghua Bing Li Xue Za Zhi 46:782–788. https://doi.org/10.3760/cma.j.issn.0529-5807.2017.11.009
Liu X, Feng Z, Wang C, Su Q, Song H, Zhang C, Huang P, Liang XJ, Dong A, Kong D, Wang W (2020) Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses. Biomaterials 230:119649. https://doi.org/10.1016/j.biomaterials.2019.119649
Liu X, Hogg GD, Denardo DG (2021a) Rethinking immune checkpoint blockade: “Beyond the T cell.” J Immunother Cancer 9:e001460. https://doi.org/10.1136/jitc-2020-001460
Liu Y, Lu X, Qin N, Qiao Y, Xing S, Liu W, Feng F, Liu Z, Sun H (2021b) STING, a promising target for small molecular immune modulator: a review. Eur J Med Chem 211:113113. https://doi.org/10.1016/j.ejmech.2020.113113
Lucas J, Hsieh TC, Halicka HD, Darzynkiewicz Z, Wu JM (2018) Upregulation of PDL1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300mediated NFkappaB signaling. Int J Oncol 53:1469–1480. https://doi.org/10.3892/ijo.2018.4512
Ludovini V, Bianconi F, Siggillino A, Vannucci J, Baglivo S, Berti V, Tofanetti FR, Reda MS, Bellezza G, Mandarano M, Belladonna ML, Metro G, Chiari R, Sidoni A, Puma F, Minotti V, Roila F (2021) High PD-L1/IDO-2 and PD-L2/IDO-1 Co-expression levels are associated with worse overall survival in resected non-small cell lung cancer patients. Genes (basel) 12:273. https://doi.org/10.3390/genes12020273
Lund AW, Duraes FV, Hirosue S, Raghavan VR, Nembrini C, Thomas SN, Issa A, Hugues S, Swartz MA (2012) VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep 1:191–199. https://doi.org/10.1016/j.celrep.2012.01.005
Mansouri K, Rasoulpoor S, Daneshkhah A, Abolfathi S, Salari N, Mohammadi M, Rasoulpoor S, Shabani S (2020) Clinical effects of curcumin in enhancing cancer therapy: a systematic review. BMC Cancer 20:791. https://doi.org/10.1186/s12885-020-07256-8
Missiaen R, Mazzone M, Bergers G (2018) The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Semin Cancer Biol 52:107–116. https://doi.org/10.1016/j.semcancer.2018.06.002
Mitani A, Jo T, Yasunaga H, Sakamoto Y, Hasegawa W, Urushiyama H, Yamauchi Y, Matsui H, Fushimi K, Nagase T (2018) Venous thromboembolic events in patients with lung cancer treated with cisplatin-based versus carboplatin/nedaplatin-based chemotherapy. Anticancer Drugs 29:560–564. https://doi.org/10.1097/CAD.0000000000000625
Moraes-Pinto MI, Suano-Souza F, Aranda CS (2021) Immune system: development and acquisition of immunological competence. J Pediatr (rio j) 97(Suppl 1):S59–S66. https://doi.org/10.1016/j.jped.2020.10.006
Mukherjee S, Baidoo JNE, Fried A, Banerjee P (2020) Using curcumin to turn the innate immune system against cancer. Biochem Pharmacol 176:113824. https://doi.org/10.1016/j.bcp.2020.113824
Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117:1147–1154. https://doi.org/10.1172/JCI31178
Nagaraj S, Gabrilovich DI (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68:2561–2563. https://doi.org/10.1158/0008-5472.CAN-07-6229
Nakamura T, Miyabe H, Hyodo M, Sato Y, Hayakawa Y, Harashima H (2015) Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. J Control Release 216:149–157. https://doi.org/10.1016/j.jconrel.2015.08.026
Nakayasu S, Soegima R, Yamaguchi K, Oda T (2009) Biological activities of fucose-containing polysaccharide ascophyllan isolated from the brown alga Ascophyllum nodosum. Biosci Biotechnol Biochem 73:961–964. https://doi.org/10.1271/bbb.80845
Newman DJ, Cragg GM (2020) Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod 83:770–803. https://doi.org/10.1021/acs.jnatprod.9b01285
Ni J, Song J, Wang B, Hua H, Zhu H, Guo X, Xiong S, Zhao Y (2020) Dendritic cell vaccine for the effective immunotherapy of breast cancer. Biomed Pharmacother 126:110046. https://doi.org/10.1016/j.biopha.2020.110046
Noori S, Hassan ZM (2011) Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo. Cell Immunol 271:67–72. https://doi.org/10.1016/j.cellimm.2011.06.008
Pan BS, Perera SA, Piesvaux JA, Presland JP, Schroeder GK, Cumming JN, Trotter BW, Altman MD, Buevich AV, Cash B, Cemerski S, Chang W, Chen Y, Dandliker PJ, Feng G, Haidle A, Henderson T, Jewell J, Kariv I, Knemeyer I, Kopinja J, Lacey BM, Laskey J, Lesburg CA, Liang R, Long BJ, Lu M, Ma Y, Minnihan EC, O'donnell G, Otte R, Price L, Rakhilina L, Sauvagnat B, Sharma S, Tyagarajan S, Woo H, Wyss DF, Xu S, Bennett DJ, Addona GH (2020) An orally available non-nucleotide STING agonist with antitumor activity. Science 369: eaba6098. https://doi.org/10.1126/science.aba6098.
Pantouris G, Mowat CG (2014) Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase. Biochem Biophys Res Commun 443:28–31. https://doi.org/10.1016/j.bbrc.2013.11.037
Park BY, Min BS, Ahn KS, Kwon OK, Joung H, Bae KH, Lee HK, Oh SR (2007) Daphnane diterpene esters isolated from flower buds of Daphne genkwa induce apoptosis in human myelocytic HL-60 cells and suppress tumor growth in Lewis lung carcinoma (LLC)-inoculated mouse model. J Ethnopharmacol 111:496–503. https://doi.org/10.1016/j.jep.2006.12.023
Patra S, Pradhan B, Nayak R, Behera C, Rout L, Jena M, Efferth T, Bhutia SK (2020) Chemotherapeutic efficacy of curcumin and resveratrol against cancer: chemoprevention, chemoprotection, drug synergism and clinical pharmacokinetics. Semin Cancer Biol 73:310–320. https://doi.org/10.1016/j.semcancer.2020.10.010
Popat R, Plesner T, Davies F, Cook G, Cook M, Elliott P, Jacobson E, Gumbleton T, Oakervee H, Cavenagh J (2013) A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br J Haematol 160:714–717. https://doi.org/10.1111/bjh.12154
Popovic A, Jaffee EM, Zaidi N (2018) Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest 128:3209–3218. https://doi.org/10.1172/JCI120775
Ramacher M, Umansky V, Efferth T (2009) Effect of artesunate on immune cells in ret-transgenic mouse melanoma model. Anticancer Drugs 20:910–917. https://doi.org/10.1097/CAD.0b013e328330caba
Rawangkan A, Wongsirisin P, Namiki K, Iida K, Kobayashi Y, Shimizu Y, Fujiki H, Suganuma M (2018) Green tea catechin is an alternative immune checkpoint inhibitor that inhibits PD-L1 expression and lung tumor growth. Molecules 23:2071. https://doi.org/10.3390/molecules23082071
Ri MH, Ma J, Jin X (2021) Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer. J Ethnopharmacol 281:114370. https://doi.org/10.1016/j.jep.2021.114370
Rodrigues T, Reker D, Schneider P, Schneider G (2016) Counting on natural products for drug design. Nat Chem 8:531–541. https://doi.org/10.1038/nchem.2479
Rossi A, Di Maio M (2016) Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. Expert Rev Anticancer Ther 16:653–660. https://doi.org/10.1586/14737140.2016.1170596
Rubel R, Santa HSD, Dos Santos LF, Fernandes LC, Figueiredo BC, Soccol CR (2018) Immunomodulatory and antitumoral properties of ganoderma lucidum and agaricus brasiliensis (agaricomycetes) medicinal mushrooms. Int J Med Mushrooms 20:393–403. https://doi.org/10.1615/IntJMedMushrooms.2018025979
Sharma RA, Mclelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP (2001) Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7:1894–1900
Shaul ME, Fridlender ZG (2019) Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol 16:601–620. https://doi.org/10.1038/s41571-019-0222-4
Shen L, Zhang J, Lee H, Batista MT, Johnston SA (2019) RNA transcription and splicing errors as a source of cancer frameshift neoantigens for vaccines. Sci Rep 9:14184. https://doi.org/10.1038/s41598-019-50738-4
Shiji R, Joseph MM, Pillai KR, Preethi GU, Sreelekha TT (2020) A biocompatible glycol-capped nano-delivery system with stimuli-responsive drug release kinetics abrogates cancer cell survival. Int J Biol Macromol 165:568–581. https://doi.org/10.1016/j.ijbiomac.2020.09.121
Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265–7279. https://doi.org/10.1038/sj.onc.1206933
Singh CK, Ndiaye MA, Ahmad N (2015) Resveratrol and cancer: challenges for clinical translation. Biochim Biophys Acta 1852:1178–1185. https://doi.org/10.1016/j.bbadis.2014.11.004
Singh AP, Singh R, Verma SS, Rai V, Kaschula CH, Maiti P, Gupta SC (2019) Health benefits of resveratrol: evidence from clinical studies. Med Res Rev 39:1851–1891. https://doi.org/10.1002/med.21565
Su T, Zhang Y, Valerie K, Wang XY, Lin S, Zhu G (2019) STING activation in cancer immunotherapy. Theranostics 9:7759–7771. https://doi.org/10.7150/thno.37574
Sun W, Li Q, Ning X, Yang Y, Guo J, Zhu Q, Guo Y, Li H, Wang Y, Zhou Y, Kou Z (2020) TFPR1 acts as an immune regulator and an efficient adjuvant for proteins and peptides by activating immune cells, primarily through TLR2. Vaccine 38:288–297. https://doi.org/10.1016/j.vaccine.2019.10.017
Tang J, Yu JX, Hubbard-Lucey VM, Neftelinov ST, Hodge JP, Lin Y (2018) Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov 17:854–855. https://doi.org/10.1038/nrd.2018.210
Tang K, Wu YH, Song Y, Yu B (2021) Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy. J Hematol Oncol 14:68. https://doi.org/10.1186/s13045-021-01080-8
Tarazona R, Lopez-Sejas N, Guerrero B, Hassouneh F, Valhondo I, Pera A, Sanchez-Correa B, Pastor N, Duran E, Alonso C, Solana R (2020) Current progress in NK cell biology and NK cell-based cancer immunotherapy. Cancer Immunol Immunother 69:879–899. https://doi.org/10.1007/s00262-020-02532-9
Uhle S, Medalia O, Waldron R, Dumdey R, Henklein P, Bech-Otschir D, Huang X, Berse M, Sperling J, Schade R, Dubiel W (2003) Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. EMBO J 22:1302–1312. https://doi.org/10.1093/emboj/cdg127
Valipour B, Velaei K, Abedelahi A, Karimipour M, Darabi M, Charoudeh HN (2019) NK cells: an attractive candidate for cancer therapy. J Cell Physiol 234:19352–19365. https://doi.org/10.1002/jcp.28657
Varghese S, Joseph MM, S RA, B SU, Sreelekha TT, (2017) The inhibitory effect of anti- tumor polysaccharide from Punica granatum on metastasis. Int J Biol Macromol 103:1000–1010. https://doi.org/10.1016/j.ijbiomac.2017.05.137
Venter C, Eyerich S, Sarin T, Klatt KC (2020) Nutrition and the immune system: a complicated tango. Nutrients 12:818. https://doi.org/10.3390/nu12030818
Verdura S, Cuyas E, Cortada E, Brunet J, Lopez-Bonet E, Martin-Castillo B, Bosch-Barrera J, Encinar JA, Menendez JA (2020) Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging (albany NY) 12:8–34. https://doi.org/10.18632/aging.102646
Villani AC, Sarkizova S, Hacohen N (2018) Systems immunology: learning the rules of the immune system. Annu Rev Immunol 36:813–842. https://doi.org/10.1146/annurev-immunol-042617-053035
Volaric A, Gentzler R, Hall R, Mehaffey JH, Stelow EB, Bullock TN, Martin LW, Mills AM (2018) Indoleamine-2,3-dioxygenase in non-small cell lung cancer: a targetable mechanism of immune resistance frequently coexpressed with PD-L1. Am J Surg Pathol 42:1216–1223. https://doi.org/10.1097/PAS.0000000000001099
Wang X, Lin Y (2008) Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 29:1275–1288. https://doi.org/10.1111/j.1745-7254.2008.00889.x
Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307–320. https://doi.org/10.1038/nrd1691
Wang JX, Tang W, Shi LP, Wan J, Zhou R, Ni J, Fu YF, Yang YF, Li Y, Zuo JP (2007) Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Br J Pharmacol 150:652–661. https://doi.org/10.1038/sj.bjp.0707137
Wang C, Shi S, Chen Q, Lin S, Wang R, Wang S, Chen C (2018) Antitumor and immunomodulatory activities of ganoderma lucidum polysaccharides in glioma-bearing rats. Integr Cancer Ther 17:674–683. https://doi.org/10.1177/1534735418762537
West H, Mccleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, Mccune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:924–937. https://doi.org/10.1016/S1470-2045(19)30167-6
Wilson DR, Sen R, Sunshine JC, Pardoll DM, Green JJ, Kim YJ (2018) Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. Nanomedicine 14:237–246. https://doi.org/10.1016/j.nano.2017.10.013
Wright GD (2019) Unlocking the potential of natural products in drug discovery. Microb Biotechnol 12:55–57. https://doi.org/10.1111/1751-7915.13351
Wu B, Hu K, Li S, Zhu J, Gu L, Shen H, Hambly BD, Bao S, Di W (2012) Dihydroartiminisin inhibits the growth and metastasis of epithelial ovarian cancer. Oncol Rep 27:101–108. https://doi.org/10.3892/or.2011.1505
Wu JJ, Zhao L, Hu HG, Li WH, Li YM (2020a) Agonists and inhibitors of the STING pathway: potential agents for immunotherapy. Med Res Rev 40:1117–1141. https://doi.org/10.1002/med.21649
Wu Y, Liu J, Movahedi F, Gu W, Xu T, Xu ZP (2020b) Enhanced prevention of breast tumor metastasis by nanoparticle-delivered vitamin E in combination with interferon-gamma. Adv Healthc Mater 9:e1901706. https://doi.org/10.1002/adhm.201901706
Xiaoguang LI, Qian BA, Jingquan LI, Hui WJCSB (2017) Anticancer effect of artemisinin and its derivatives: research progress, mechanism of action and future perspectives. Chin Ence Bull 62:1964–1972. https://doi.org/10.1007/s00280-017-3251-7 (Epub 2017 Feb 16)
Xu Z, Chen X, Zhong Z, Chen L, Wang Y (2011) Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities. Am J Chin Med 39:15–27. https://doi.org/10.1142/S0192415X11008610
Xu B, Yu L, Zhao LZ (2017) Curcumin up regulates T helper 1 cells in patients with colon cancer. Am J Transl Res 9:1866–1875
Xu L, Zhang Y, Tian K, Chen X, Zhang R, Mu X, Wu Y, Wang D, Wang S, Liu F, Wang T, Zhang J, Liu S, Zhang Y, Tu C, Liu H (2018) Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects. J Exp Clin Cancer Res 37:261. https://doi.org/10.1186/s13046-018-0929-6
Yang Y, Paik JH, Cho D, Cho JA, Kim CW (2008) Resveratrol induces the suppression of tumor-derived CD4+CD25+ regulatory T cells. Int Immunopharmacol 8:542–547. https://doi.org/10.1016/j.intimp.2007.12.006
Yang S, Li X, Hu F, Li Y, Yang Y, Yan J, Kuang C, Yang Q (2013) Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. J Med Chem 56:8321–8331. https://doi.org/10.1021/jm401195n
Yang W, Yang S, Zhang F, Cheng F, Wang X, Rao J (2020) Influence of the Hippo-YAP signalling pathway on tumor associated macrophages (TAMs) and its implications on cancer immunosuppressive microenvironment. Ann Transl Med 8:399. https://doi.org/10.21037/atm.2020.02.11
Yao W, Ba Q, Li X, Li H, Zhang S, Yuan Y, Wang F, Duan X, Li J, Zhang W, Wang H (2017) A natural CCR2 antagonist relieves tumor-associated macrophage-mediated immunosuppression to produce a therapeutic effect for liver cancer. EBioMedicine 22:58–67. https://doi.org/10.1016/j.ebiom.2017.07.014
Yao C, Ni Z, Gong C, Zhu X, Wang L, Xu Z, Zhou C, Li S, Zhou W, Zou C, Zhu S (2018) Rocaglamide enhances NK cell-mediated killing of non-small cell lung cancer cells by inhibiting autophagy. Autophagy 14:1831–1844. https://doi.org/10.1080/15548627.2018.1489946
Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA (2021) Development of immunotherapy combination strategies in cancer. Cancer Discov 11:1368–1397. https://doi.org/10.1158/2159-8290.CD-20-1209
Yu H, Yang Y, Jiang T, Zhang X, Zhao Y, Pang G, Feng Y, Zhang S, Wang F, Wang Y, Wang Y, Zhang LW (2019) Effective radiotherapy in tumor assisted by ganoderma lucidum polysaccharide-conjugated bismuth sulfide nanoparticles through radiosensitization and dendritic cell activation. ACS Appl Mater Interfaces 11:27536–27547. https://doi.org/10.1021/acsami.9b07804
Yunna C, Mengru H, Lei W, Weidong C (2020) Macrophage M1/M2 polarization. Eur J Pharmacol 877:173090. https://doi.org/10.1016/j.ejphar.2020.173090
Zhang L, Yu JS (2019) Triptolide reverses helper T cell inhibition and down-regulates IFN-gamma induced PD-L1 expression in glioma cell lines. J Neurooncol 143:429–436. https://doi.org/10.1007/s11060-019-03193-0
Zhang Y, Zheng J (2020) Functions of immune checkpoint molecules beyond immune evasion. Adv Exp Med Biol 1248:201–226. https://doi.org/10.1007/978-981-15-3266-5_9
Zhang J, Tang Q, Zhou C, Jia W, Da Silva L, Nguyen LD, Reutter W, Fan H (2010) GLIS, a bioactive proteoglycan fraction from Ganoderma lucidum, displays anti-tumour activity by increasing both humoral and cellular immune response. Life Sci 87:628–637. https://doi.org/10.1016/j.lfs.2010.09.026
Zhang LX, Liu ZN, Ye J, Sha M, Qian H, Bu XH, Luan ZY, Xu XL, Huang AH, Yuan DL, Wu YQ, Wang XX, Wang J, Huang JX, Ye LH (2014a) Artesunate exerts an anti-immunosuppressive effect on cervical cancer by inhibiting PGE2 production and Foxp3 expression. Cell Biol Int 38:639–646. https://doi.org/10.1002/cbin.10244
Zhang W, Du JY, Jiang Z, Okimura T, Oda T, Yu Q, Jin JO (2014b) Ascophyllan purified from Ascophyllum nodosum induces Th1 and Tc1 immune responses by promoting dendritic cell maturation. Mar Drugs 12:4148–4164. https://doi.org/10.3390/md12074148
Zhang W, Oda T, Yu Q, Jin JO (2015) Fucoidan from Macrocystis pyrifera has powerful immune-modulatory effects compared to three other fucoidans. Mar Drugs 13:1084–1104. https://doi.org/10.3390/md13031084
Zhang W, Okimura T, Xu L, Zhang L, Oda T, Kwak M, Yu Q, Jin JO (2016) Ascophyllan functions as an adjuvant to promote anti-cancer effect by dendritic cell activation. Oncotarget 7:19284–19298. https://doi.org/10.18632/oncotarget.8200
Zhang D, Zhou J, Tang D, Zhou L, Chou L, Chou KY, Tao L, Lu LM (2017) Neutrophil infiltration mediated by CXCL5 accumulation in the laryngeal squamous cell carcinoma microenvironment: a mechanism by which tumour cells escape immune surveillance. Clin Immunol 175:34–40. https://doi.org/10.1016/j.clim.2016.11.009
Zhang Y, Sun Z, Pei J, Luo Q, Zeng X, Li Q, Yang Z, Quan J (2018) Identification of alpha-Mangostin as an Agonist of Human STING. ChemMedChem 13:2057–2064. https://doi.org/10.1002/cmdc.201800481
Zhang S, Pang G, Chen C, Qin J, Yu H, Liu Y, Zhang X, Song Z, Zhao J, Wang F, Wang Y, Zhang LW (2019a) Effective cancer immunotherapy by Ganoderma lucidum polysaccharide-gold nanocomposites through dendritic cell activation and memory T cell response. Carbohydr Polym 205:192–202. https://doi.org/10.1016/j.carbpol.2018.10.028
Zhang W, Kwak M, Park HB, Okimura T, Oda T, Lee PC, Jin JO (2019b) Activation of human dendritic cells by ascophyllan purified from Ascophyllum nodosum. Mar Drugs 17:66. https://doi.org/10.3390/md17010066
Zhang DKY, Cheung AS, Mooney DJ (2020a) Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds. Nat Protoc 15:773–798. https://doi.org/10.1038/s41596-019-0249-0
Zhang H, Tan YP, Zhao L, Wang L, Fu NJ, Zheng SP, Shen XF (2020b) Anticancer activity of dietary xanthone alpha-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1. Cell Death Dis 11:63. https://doi.org/10.1038/s41419-020-2227-4
Zhang Q, Ping J, Huang Z, Zhang X, Zhou J, Wang G, Liu S, Ma J (2020c) CAR-T cell therapy in cancer: tribulations and road ahead. J Immunol Res 2020:1924379. https://doi.org/10.1155/2020/1924379
Zhao H, Sun P, Guo W, Wang Y, Zhang A, Meng L, Ding C (2019) Discovery of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitors based on ortho-naphthaquinone-containing natural product. Molecules 24:1059. https://doi.org/10.3390/molecules24061059
Zhao Q, Liu C, Liu H, Chen J (2020) Advances in immune neoadjuvant/adjuvant therapy-related adverse events of non-small cell lung cancer. Asia Pac J Clin Oncol. https://doi.org/10.1111/ajco.13378
Zou JY, Su CH, Luo HH, Lei YY, Zeng B, Zhu HS, Chen ZG (2018) Curcumin converts Foxp3+ regulatory T cells to T helper 1 cells in patients with lung cancer. J Cell Biochem 119:1420–1428. https://doi.org/10.1002/jcb.26302
Acknowledgements
This study was funded by the National Natural Science Foundation of China (81873045), Joint Funds for the Innovations of Science and Technology, Fujian Province (2020GGA015, 2021J01608, 2018Y0015 and 2018Y2003), the Natural Science Foundation of Fujian Province (2020J011118 and 2020J011115), the Fuzhou University Testing Fund of precious apparatus (No. 2020T022) and the “Young Top Creative Talents” of the Second Batch Special Support “Double Hundred Plan” of Fujian Province.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yang, Y., Liu, Q., Shi, X. et al. Advances in plant-derived natural products for antitumor immunotherapy. Arch. Pharm. Res. 44, 987–1011 (2021). https://doi.org/10.1007/s12272-021-01355-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-021-01355-1